OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Consensus Target Price from Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $9.06.

OPRX has been the subject of a number of research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. William Blair reiterated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Stifel Nicolaus cut their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Stephens began coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target for the company. Finally, JMP Securities lowered their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th.

Insider Buying and Selling at OptimizeRx

In related news, CEO William J. Febbo acquired 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the transaction, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of OptimizeRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Greenwood Capital Associates LLC increased its position in OptimizeRx by 31.5% during the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company’s stock worth $431,000 after buying an additional 21,240 shares during the period. SG Americas Securities LLC acquired a new stake in OptimizeRx during the fourth quarter worth about $51,000. Barclays PLC raised its position in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares in the last quarter. Bullseye Asset Management LLC lifted its holdings in shares of OptimizeRx by 55.6% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after acquiring an additional 76,458 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Up 0.9 %

OptimizeRx stock opened at $5.71 on Tuesday. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average of $5.18 and a 200-day moving average of $6.74. The stock has a market capitalization of $105.18 million, a PE ratio of -4.29 and a beta of 1.36.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.